| Features: |
| Ramucirumab (CYRAMZA) is a fully human IgG1 monoclonal antibody that binds VEGFR-2 (KDR/Flk-1) on endothelial cells and blocks VEGF-A/VEGF-C/VEGF-D from activating the receptor, thereby suppressing VEGFR-2 phosphorylation and downstream pro-angiogenic signaling (endothelial proliferation, migration, survival, and vascular permeability). Clinically, it’s used as an anti-angiogenic therapy across multiple solid tumors (labelled indications include advanced/metastatic gastric/GEJ adenocarcinoma, NSCLC in specific combinations/settings, metastatic colorectal cancer in combination therapy, and AFP-high hepatocellular carcinoma after prior therapy). Pathways/axes ramucirumab functionally down-modulates (via VEGFR-2 blockade) -VEGF ligand → VEGFR-2 angiogenesis axis (core target): vessel sprouting, endothelial survival, migration, permeability. -PI3K → AKT (PKB) survival signaling downstream of VEGFR-2 (endothelial cell survival/anti-apoptosis). -RAS → RAF → MEK → ERK (MAPK) proliferation signaling downstream of VEGFR-2 (endothelial proliferation). -PLCγ → PKC signaling downstream of VEGFR-2 (linked to permeability and other endothelial responses). -Src-family kinases / TSAd–Src modules and FAK/integrin–cytoskeleton signaling (migration, adhesion, barrier regulation). -eNOS → nitric oxide (NO) signaling (vascular tone/permeability; intersects with Src and PLCγ signaling). -Vascular permeability & “vascular normalization” effects that can secondarily modulate tumor hypoxia/HIF programs and immune cell trafficking/antitumor immunity in the microenvironment (context-dependent). |
| Source: |
| Type: |
| The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”. Chemo-Sensitizers: -Curcumin -Resveratrol -EGCG -Quercetin -Genistein -Berberine -Piperine: alkaloid from black pepper -Ginsenosides: active components of ginseng -Silymarin -Allicin -Lycopene -Ellagic acid -caffeic acid phenethyl ester -flavopiridol -oleandrin -ursolic acid -butein -betulinic acid |
| 5284- | Ramu, | https://pmc.ncbi.nlm.nih.gov/articles/PMC4131847/ |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:229 Target#:1106 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid